To include your compound in the COVID-19 Resource Center, submit it here.

Emricasan: Phase II started

Conatus began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 25 mg oral emricasan twice daily for 3 months in about 80

Read the full 237 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE